NAVCO Pharmaceuticals Balance Sheet

Financials in millions CAD. Fiscal year is October - September.

Millions CAD. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Cash & Equivalents	0	0	0.01	0.23	0	0
Cash & Short-Term Investments	0	0	0.01	0.23	0	0
Cash Growth	-87.91%	-59.39%	-96.87%	15187.95%	-62.29%	-
Other Receivables	-	-	0.07	0.05	0.06	0.03
Receivables	-	-	0.07	0.05	0.06	0.03
Inventory	-	-	-	0	0	0.01
Prepaid Expenses	-	-	-	0.43	-	-
Total Current Assets	0	0	0.07	0.71	0.06	0.04
Property, Plant & Equipment	-	-	0	0.18	0.22	0.25
Other Intangible Assets	-	-	-	0.04	0.05	0.05
Total Assets	0	0	0.08	0.93	0.32	0.35
Accounts Payable	0.19	0.19	0.17	0.11	0.17	0.08
Accrued Expenses	0.04	0.04	0.03	0.13	0.04	0.01
Short-Term Debt	0.11	0.09	0.09	0.01	0.78	0.17
Current Portion of Leases	-	-	0.01	0.01	0.01	0.01
Other Current Liabilities	0.63	0.63	0.63	0.49	-	0.29
Total Current Liabilities	0.96	0.94	0.93	0.75	1.01	0.56
Long-Term Leases	-	-	-	0.09	0.1	0.12
Total Liabilities	0.96	0.94	0.93	0.84	1.11	0.67
Common Stock	4.02	4.02	4.02	3.35	0.88	0.88
Retained Earnings	-5.64	-5.61	-5.53	-3.81	-1.66	-1.2
Comprehensive Income & Other	0.66	0.66	0.66	0.55	-	-
Shareholders' Equity	-0.96	-0.94	-0.86	0.09	-0.79	-0.32
Total Liabilities & Equity	0	0	0.08	0.93	0.32	0.35
Total Debt	0.11	0.09	0.1	0.11	0.9	0.29
Net Cash (Debt)	-0.1	-0.08	-0.09	0.12	-0.9	-0.29
Net Cash Per Share	-0.00	-0.00	-0.00	0.00	-0.04	-0.02
Filing Date Shares Outstanding	57.07	57.07	57.07	40.35	14.5	14.48
Total Common Shares Outstanding	57.07	57.07	57.07	40.35	14.5	14.48
Working Capital	-0.96	-0.94	-0.86	-0.04	-0.95	-0.52
Book Value Per Share	-0.02	-0.02	-0.02	0.00	-0.05	-0.02
Tangible Book Value	-0.96	-0.94	-0.86	0.05	-0.83	-0.38
Tangible Book Value Per Share	-0.02	-0.02	-0.02	0.00	-0.06	-0.03
Machinery	-	0.03	0.03	0.1	0.1	0.1
Leasehold Improvements	-	0.04	0.04	0.05	0.05	0.05